Mr. Bihlet is an internationally renowned expert in osteoarthritis (OA) drug development, OA pain, and clinical trial design. After receiving his MSc. in pharmaceutical sciences from the University of Copenhagen, Mr. Bihlet has held several leading positions in pharma and clinical research organizations within regulatory affairs, medical affairs, and clinical science. He has published more than 25 peer-reviewed papers on OA science in high-ranking journals and has been cited more than 1,000 times. Mr. Bihlet has played key roles in the design and conduct of landmark osteoarthritis trials, including the sprifermin FORWARD trial published in JAMA in 2019, and is a frequent speaker at OARSI, EULAR, and ACR conferences, where more than 50 original abstracts have been presented, in addition to invited speaker sessions on OA trial design and placebo response mitigation. As Chief Scientific Officer, he currently leads the scientific affairs activities of Sanos Group and the subsidiary of NBCD A/S, a Contract Research Organization specializing in OA clinical trials. As chief scientist, he was the person primarily responsible for the design and conduct of three global phase III, 15 phase II and five phase I trials totaling approximately 10,000 study participants evaluating experimental treatments primarily within knee osteoarthritis. Mr. Bihlet is actively researching in the fields of osteoarthritis with a particular focus on optimizing clinical methodology and outcome.
